NASDAQ:SUPN
Supernus Pharmaceuticals Stock News
$27.87
-0.180 (-0.642%)
At Close: May 22, 2024
Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates
06:49pm, Tuesday, 28'th Feb 2023
Supernus (SUPN) delivered earnings and revenue surprises of -41.10% and 8.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus Enters Into $150 Million Credit Facility
09:30pm, Tuesday, 14'th Feb 2023 GlobeNewswire Inc.
ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
11:15pm, Thursday, 09'th Feb 2023 GlobeNewswire Inc.
ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
06:15pm, Thursday, 09'th Feb 2023
ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
10:00pm, Tuesday, 22'nd Nov 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
05:00pm, Tuesday, 22'nd Nov 2022
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates
12:25am, Wednesday, 09'th Nov 2022 Zacks Investment Research
Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus to Present at Two November Healthcare Conferences
10:30pm, Tuesday, 08'th Nov 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates
09:04pm, Tuesday, 08'th Nov 2022
Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2022 Earnings Call Transcript
05:42pm, Tuesday, 08'th Nov 2022
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Exe
Supernus to Present at Two November Healthcare Conferences
05:30pm, Tuesday, 08'th Nov 2022
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
08:30pm, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
04:30pm, Tuesday, 25'th Oct 2022
ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Provides Regulatory Update on SPN-830
12:30pm, Monday, 10'th Oct 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
04:00pm, Wednesday, 31'st Aug 2022
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
